

Insights from CSD crystallographic data applied to drug discovery

Neysa Nevins ACS National Meeting San Diego, CA August 28, 2019




- 1995-1999: checking torsions during post-doc at Emory University
- 1999-2001: teaching molecular structure at Elizabethtown College
- 2002-present: I became CSD point of contact for GSK US computational chemistry group
 - Not clear who else in GSK used it (e.g. folks in Product Development)
 - Our UK comp chem group used more extensively, Colin Edge & Roy Copley
 - I'm still mostly using CSD to check torsions

Rookie mistake: sulfonamide torsion

Circa 2002





- Accept docking pose with NH eclipsing phenyl?
- Every time torsion question arose needed to fire-up Conquest and search
- Often waited too long and allowed poor torsion to carry through in my proposed docking poses




- 1995-1999: checking torsions during post-doc at Emory University
- 1999-2001: teaching about molecular structure at Elizabethtown College
- 2002-present: became CSD point of contact for GSK US computational chemistry group
 - Not clear who else in GSK used it (e.g. folks in Product Development)
 - Our UK comp chem group used more extensively, Colin Edge & Roy Copley
 - I still mostly used CSD to check torsions
- 2013: Met JW Feng at CCG UGM who shared Mogul analysis tool integrated into MOE

Since ~2015: Mogul Analysis integrated in MOE & Maestro



Soon?: Ligand pose "Mogul Analysis" integrated into docking workflows





- 1995-1999: checking torsions during post-doc at Emory University
- 1999-2001: teaching about molecular structure at Elizabethtown College
- 2002-present: became CSD point of contact for GSK US computational chemistry group
 - Not clear who else in GSK used it (e.g. folks in Product Development)
 - Our UK comp chem group used more extensively, Colin Edge & Roy Copley
 - I still mostly used CSD to check torsions
- 2013: Met JW Feng at CCG UGM who shared Mogul analysis tool integrated into MOE
- 2014: Attended first US Research Partner meeting at Rutgers
 - Colin Groom presented interesting examples
 - Downloaded his presentations from following Spring 2015 UK RP meeting

Interaction propensity

Groom, US RP meeting 9/2014



Base type	Contact type	R _F	Rank
Br(-)	H(polar)	9.43	1
CI(-)	H(polar)	7.73	2
I	N(acc)	5.68	3
0	H(polar)	5.13	4
H(polar)	CI(-)	5.11	5
N(acc)	H(polar)	4.96	6
H(polar)	Br(-)	4.86	7
H(polar)	N(acc)	4.36	8
H(polar)	0	3.83	9
1	0	2.80	10


Interaction	R _F
FH(C)	1.84
FF	1.11
FCl	1.00
FBr	0.86
FH(polar)	0.63
FC(sat)	0.59
FC(unsat)	0.55
FI	0.52
FO	0.41
FN(nonacc)	0.38
FN(acc)	0.23

Ratio (R_F) of observed frequency of occurrence to the frequency expected at random

Well-placed methyl group improves solubility

Groom, US RP meeting 9/2014





Certal et al. J. Med. Chem. 2014 57 (3) pp 903-920 DOI: 10.1021/jm401642q (Sanofi, PI3K inhibitors)


Solubility governed by log P and Melting Point





Compounds may be less water soluble if

- They are lipophilic
- They form cohesive, stable crystalline lattices...




Jain, N.; Yalkowsky, S.H. J. Pharm. Sci. 2001, 90(2) 234-252 Wassvik et al., J. Med. Chem. 2008, 51 (10), pp 3035–3039 DOI: 10.1021/jm701587d

 S_0 = intrinsic solubility

Solubility by design with three replacements

Groom, UK RP meeting 3/2015





GPR 119 agonists

Scott et al., J. Med. Chem., 2012, 55 (11), pp 5361-5379 DOI: 10.1021/jm300310c Scott et al., J. Med. Chem., 2014, 57 (21), pp 8984–8998 DOI: 10.1021/jm5011012




- 1995-1999: checking torsions during post-doc at Emory University
- 1999-2001: teaching about molecular structure at Elizabethtown College
- 2002-present: became CSD point of contact for GSK US computational chemistry group
 - Not clear who else in GSK used it (e.g. folks in Product Development)
 - Our UK comp chem group used more extensively, Colin Edge & Roy Copley
 - I still mostly used CSD to check torsions
- 2013: Met JW Feng at CCG UGM who shared Mogul analysis tool integrated into MOE
- 2014: Attended first US Research Partner meeting at Rutgers
- 2015: Attended second US Research Partner meeting at Rutgers


Solubility (CI -> H)

Groom, US RP meeting 10/2015





Frey et al., J. Med. Chem., 2015, 58 (6), pp 2737–2745 DOI: 10.1021/jm501908a




Solubility $< 10.8 \mu g/ml$

Solubility = $510 \mu g/ml$

Full interaction maps in Mercury

Groom, US RP meeting 10/2015








- 1995-1999: checking torsions during post-doc at Emory University
- 1999-2001: teaching about molecular structure at Elizabethtown College
- 2002-present: became CSD point of contact for GSK US computational chemistry group
 - Not clear who else in GSK used it (e.g. folks in Product Development)
 - Our UK comp chem group used more extensively, Colin Edge & Roy Copley
 - I still mostly used CSD to check torsions
- 2013: Met JW Feng at CCG UGM who shared Mogul analysis tool integrated into MOE
- 2014: Attended first US Research Partner meeting at Rutgers
- 2015: Attended second US Research Partner meeting at Rutgers
- 2016-2018: More regular visits from CCDC scientists to GSK to highlight capabilities
- Recent CSD insights for project support:
 - Aminobenzimidazole tautomer
 - Triazole tautomer

Aminobenzimidazole (ABZI) hit binds to STING

Ramanjulu et. al., Nature **564**, 439-443 (2018)







Aminobenzimidazole (ABZI) tautomer insights





Two possibilities for proton location





Quantum mechanics calculations favor tautomer #2





Aminobenzimidazole (ABZI) tautomer insights

CSD search with amide



Three possibilities for proton location






RIP1 inhibitor with triazole







	S
40	
es	S
$\stackrel{\square}{=}$	0
\supset	0
9	0
	Ĺ
9	Ę
2	
Ф	=
	_

Structure	Supplier	Catalog Number	CAS Number
tautomer #2 (2 vendors)	Aurum Pharmatech	AR36152	648430-85-7
N	Enamine BB - EU Stock	EN300-211066	648430-85-7
MH MH			
View Compound Info	AA Blocks LLC	AA00EL0U	648430-85-7
H.C.	Aldlab Chemicals	KH-56473	648430-85-7
*	Angene Chemical	AG00EL3M	648430-85-7
tautomer #1	AstaTech	C10548	648430-85-7
(6 vendors)	ChemScene	CS-B1347	648430-85-7
View Compound Info	Key Organics/BIONET - Building Blocks	CS-13160	648430-85-7

Ligands with triazoles in PDB

Downloaded via PSILO



33 ligand exemplars with this PDB depiction

1V97	3KQB	5B5P	50WZ	5XDS
1WBG	3RTP	5CNM	50X1	5XYY
2GZ8	4CC5	5LRC	5P93	6DGT
3CQU	4CL6	5LSC	5QK1	6F3J
3DB6	4KLB	5N4N	5TX5	6QEJ
3E7O	4NI1	5NR8	5UVC	6RLN
3IU9	5B5O	5054		

N—NH c1n[nH]cn1

2J94 4BTW
2OAZ 4J99

14 ligand exemplars with this PDB depiction

2J94 4BTW 2OAZ 4IJ9 3AM9 4NI0 3G1L 4Q2F 3PTG 4TZ2 3SMI 5EI4 4B0C 5JCB

Upon visual inspection with receptor/water environment

Depicted	#1 by visual inspection	#2 by visual inspection	Can't assign	
Tautomer #1	6	12	15	
Tautomer #2	0	8	6	


	Taut	omer	#1	Tautomer	#2
PDB	depicted	33		14	
PDB	receptor/h2o	6		20	


Triazole tautomer

Vendor and CSD database searches



Two triazole proton locations





Triazole not charged (positive or negative)



- 1995-1999: checking torsions during post-doc at Emory University
- 1999-2001: teaching about molecular structure at Elizabethtown College
- 2002-present: became CSD point of contact for GSK US computational chemistry group
 - Not clear who else in GSK used it (e.g. folks in Product Development)
 - Our UK comp chem group used more extensively, Colin Edge & Roy Copley
 - I still mostly used CSD to check torsions
- 2013: Met JW Feng at CCG UGM who shared Mogul analysis tool integrated into MOE
- 2014: Attended first US Research Partner meeting at Rutgers
- 2015: Attended second US Research Partner meeting at Rutgers
- 2016-2018: More regular visits from CCDC scientists to GSK to highlight capabilities
- Recent CSD insights for project support:
 - Aminobenzimidazole tautomer
 - Triazole tautomer
- 2018: GSK internal version of WebCSD (experimentalists more likely to access)
 - Fall visit to GSK (PA) by CCDC CEO (Jürgen Harter) and Dir of Business Dev (Jonathan Betts)
- 2019: Informal CCDC US open house at co-working space in Princeton, NJ
 - Discussion with Ian Bruno & Paul Labute to integrate Full Interaction Maps (FIMs) into MOE
- ACS Fall 2019 One Million Crystal Structures Symposium

Wish list

gsk

More tools to prospectively leverage CSD data

- Integration of CSD data into existing vendor software (e.g. Maestro, MOE) for solubility prediction, conformer analysis√, tautomer prediction, interaction hotspots, etc
- Integration into workflow platforms, e.g. LiveDesign, Orion, Pipeline Pilot
- User community to discuss priorities academic and/or industrial, in Slack or MS Teams

Neysa.2.Nevins@gsk.com
Twitter: @neysanev

00	Open Live Report + My Compo	unds ▼	FaSSIF Solubility (confidence)	CSD Solubility (confidence)	Mogul outlier torsion(s)
	O NH O	V118258777	0.45	0.39	<u>Link</u>
© ()	O NH O NH O	V118258778	0.41	0.37	<u>Link</u>
	3 NH O	V118258779	0.49	0.55	
	HO 0 Br	V118258780	0.47	0.38	<u>Link</u>
? Row Per	5 H,C-0	V118258781	0.48	0.39	